Cidara Therapeutics

Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of novel anti-infectives. Its product pipeline includes Rezafungin and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of therapeutics for patients facing serious diseases, specifically oncology and infectious diseases. Its product pipeline includes Rezafungin Acetate and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.

SAN DIEGO, March 07, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today announced the closing of its previously announced concurrent but separate underwritten public offerings of 11,086,000 shares of its common stock, including the exercise in full by the underwriter of its option to purchase an additional 1,446,000 shares of common stock, and 286,000 shares of its Series X Convertible Preferred Stock (each share of which is initially convertible into 10 shares of common stock), for aggregate gross proceeds of approximately $19.5 million, before deducting underwriting discounts and commissions and estimated offering expenses.

Cidara Therapeutics Announces Closing of Public Offerings of Common Stock and Preferred Stock and Full Exercise of Underwriter's Option to Purchase Additional Shares in Public Offering of Common Stock

SAN DIEGO, March 03, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today announced the pricing of concurrent but separate underwritten public offerings of 9,640,000 shares of its common stock and 286,000 shares of its Series X Convertible Preferred Stock (each share of which is initially convertible into 10 shares of common stock), for aggregate expected gross proceeds of approximately $17.5 million, before deducting underwriting discounts and commissions and estimated offering expenses. The offerings are expected to close on or about March 7, 2023, subject to satisfaction of customary closing conditions. The closing of each offering is not contingent upon the closing of the other.

Cidara Therapeutics Announces Pricing of Public Offerings of Common Stock and Preferred Stock

SAN DIEGO, March 02, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today announced concurrent but separate underwritten public offerings of its common stock and its Series X Convertible Preferred Stock. The closing of each proposed offering is not contingent upon the closing of the other. All shares to be sold in the offerings will be sold by Cidara, subject to customary closing conditions.

Cidara Therapeutics Announces Underwritten Public Offerings of Common Stock and Preferred Stock

Amarin Corporation Plc

iBio

Sidus Space

Vascular Biogenics

Penny stocks to watch this week. The post Penny Stocks To Buy: 5 To Watch Before Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Buy: 5 To Watch Before Next Week

SAN DIEGO, March 01, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today announced promising efficacy and safety data from a planned interim analysis of the ongoing Phase 2a trial evaluating the pre-exposure prophylactic activity of CD388 against the H3N2 influenza A virus strain, as of a February 13, 2023 data cut-off. As evidenced by animal efficacy studies, CD388 has the potential to be a long-acting antiviral drug designed to deliver universal prevention of seasonal and pandemic influenza A and B strains. The study is being conducted under an exclusive worldwide license and collaboration agreement with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop and commercialize Cidara's Cloudbreak® drug-Fc conjugates (DFCs) for the prevention of seasonal and pandemic influenza.

Cidara Therapeutics Announces Promising Interim Phase 2a Data Assessing the Safety and Efficacy of a Single Dose of CD388 in an Influenza Challenge Model

SAN DIEGO, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today announced that it will present highlights from pharmacokinetic studies of a CD73-targeting drug-Fc conjugate (DFC) oncology candidate from the Company's Cloudbreak® platform at the ESMO Targeted Anticancer Therapies Congress (ESMO TAT) in Paris, March 6-8, 2023. The studies evaluated the inhibition of CD73 in cell-free and cell-based assays.

Cidara to Present at ESMO Targeted Anticancer Therapies Congress

SAN DIEGO, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today announced that it has received formal notice from The Nasdaq Stock Market, LLC (“Nasdaq”), stating that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”).

Cidara Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Agreement builds upon the existing relationship with WuXi XDC for CMC development and GMP manufacturing of Cidara's CD388 drug-Fc conjugate (DFC) for influenza to now include the oncology program Agreement builds upon the existing relationship with WuXi XDC for CMC development and GMP manufacturing of Cidara's CD388 drug-Fc conjugate (DFC) for influenza to now include the oncology program

Cidara Therapeutics and WuXi XDC Expand Collaboration for IND-enabling CMC Development to Advance Cidara's CD73 Oncology DFC Program

Today, we are putting the spotlight on small biotech concern Cidara Therapeutics for the first time in more than a year and a half. The company has an impressive set of collaboration deals with larger drug firms and its first FDA approval is on the near-term horizon.

Cidara Therapeutics: FDA Approval Dead Ahead

SAN DIEGO & PARSIPPANY, N.J.--( BUSINESS WIRE )--Cidara Therapeutics, Inc. (Nasdaq: CDTX) and Melinta Therapeutics, LLC today announced that the U.S. Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee voted favorably 14 to 1 that Cidara, as part of its New Drug Application (NDA), provided sufficient evidence supporting a favorable benefit-risk assessment for a limited use indication for rezafungin for the treatment of candidemia and invasive candidiasis in adult patients with limited or no alternative treatment options.

Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis

CBO-212 is a first-in-class inhibitor of CD73 cancer immunotherapy target CBO-212 is a first-in-class inhibitor of CD73 cancer immunotherapy target

Cidara Therapeutics Nominates First Oncology Clinical Development Candidate from its Cloudbreak® Platform

Initial CD388 clinical data expected in the first half of 2023 Initial CD388 clinical data expected in the first half of 2023

Cidara Therapeutics Announces Issuance of First U.S. Patent for CD388

SAN DIEGO, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that Institutional Shareholder Services (ISS) and Glass Lewis and Co, LLC, two leading, independent proxy advisory firms, have both recommended that stockholders vote “FOR” the proposed reverse stock split at the Company's upcoming Special Meeting of Stockholders, scheduled for Thursday, December 15, 2022 at 8:00 a.m. PST.

Cidara Therapeutics Announces Two Leading Independent Proxy Advisory Firms Recommend Stockholders Vote “FOR” Proposed Reverse Stock Split

Publication details the efficacy and safety of rezafungin dosed once-weekly versus the current of care dosed once-daily

Cidara Therapeutics and Melinta Therapeutics Announce Publication of Data from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis in The Lancet

SAN DIEGO, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that Jeff Stein, Ph.D., President and CEO, will participate in a panel discussion at the World Antiviral Congress being held in San Diego, California from November 28-December 1, 2022.

Cidara Therapeutics to Participate in the World Antiviral Congress 2022

Rezafungin has an FDA approval deadline of March 22, 2023. The stock has been neglected by investors.

Cidara Therapeutics Could Soar On Rezafungin Approval

SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will present at the Stifel Healthcare Conference.

Cidara Therapeutics to Present at the Stifel Healthcare Conference

Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -43.33% and 8.65%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Cidara Therapeutics (CDTX) Q3 Earnings Miss Estimates

SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today reported financial results for the third quarter ended September 30, 2022 and provided an update on its corporate activities and product pipeline.

Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results

SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that it is presenting new clinical and preclinical data for rezafungin in six poster presentations at IDWeek taking place in-person in Washington, D.C. from October 19-23, 2022. The company will also participate in a pipeline symposium focused on new antimicrobials and ID diagnostics.

Cidara Therapeutics to Present New Data for Rezafungin at IDWeek 2022

Milestone payment triggered by European Medicines Agency acceptance of marketing authorization application for rezafungin

Cidara Therapeutics Receives $11.1 Million Milestone Payment from Mundipharma

Assigned PDUFA target action date of March 22, 2023 Assigned PDUFA target action date of March 22, 2023

Cidara Therapeutics Announces FDA Acceptance for Priority Review of New Drug Application for Rezafungin for the Treatment of Candidemia and Invasive Candidiasis

CD388 is a drug-Fc conjugate (DFC) from Cidara's Cloudbreak ® platform designed to help transform the standard of care for seasonal and pandemic influenza prevention

Cidara Therapeutics Announces Initiation of Phase 2a Human Viral Challenge Trial to Evaluate CD388 for Universal Prevention of Influenza

SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in the 24th Annual H.C. Wainwright Global Investment Conference.

Cidara Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference

SAN DIEGO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today reported financial results for the second quarter ended June 30, 2022 and provided an update on its corporate activities and product pipeline.

News for Cidara Therapeutics Stock (CDTX)